Artiva (ARTV) Director Laura Stoppel Receives Option Award

What Happened
Laura Stoppel, a director of Artiva Biotherapeutics (ARTV) and a Partner at RA Capital Management, was granted a stock option to acquire 16,250 shares of Artiva common stock on 2026-09-10. The Form 4 reports the award as a derivative grant (code A) with an acquisition amount shown as $0.00. This is a grant/award (not an immediate purchase or sale) and the option vests on the earlier of September 10, 2027 or the Issuer’s 2027 annual meeting, subject to her continued service.

Key Details

• Transaction date: 2026-09-10; Form filed: 2026-09-14 (timely filing).
• What was granted: option covering 16,250 shares; reported acquisition price $0.00 (derivative grant).
• Shares owned after transaction: not disclosed in the filing.
• Vesting: earlier of Sept 10, 2027 or the 2027 annual stockholder meeting, subject to continuous board service.
• Footnotes: RA Capital Management, L.P. (a 10% owner) reported but disclaims beneficial ownership of the option and underlying shares; under the arrangement, Dr. Stoppel holds the option for the benefit of certain RA Capital funds and must turn over any net cash/stock received on exercise to the Adviser to offset advisory fees.

Context
This filing documents a director option grant — a common form of board compensation — rather than an exercised option or a market transaction. Because the option vests in the future and the reporting parties disclaim beneficial ownership (the option is held for the benefit of RA Capital funds and proceeds are used to offset fees), this does not reflect an immediate change in market exposure by the reporting funds or a direct cash purchase by the director.